跳至主要内容
临床试验/CTIS2023-506052-24-00
CTIS2023-506052-24-00进行中(未招募)1 期

Ketamine for combined depression and alcohol use disorder: A blinded randomized active placebo-controlled trial (the KeDA trial) - 2022/484848

niversity Hospital Of North Norway HF0 个研究点目标入组 34 人开始时间: 2023年10月25日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
34

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)
性别
All

入选标准

  • 18-65 years of age, At least moderate depression without psychotic features, Alcohol dependence as their primary substance use disorder, Must be admitted to the hospital for inpatient addiction therapy at one of the inpatient units at University Hospital of North Norway

排除标准

  • Not able to provide adequate informed consent, Illegal use of ketamine the last 6 months, Current or past history of psychotic disorder, Significant cardiovascular event during the last year, Liver failure or impariment of liver function, Significant chronic kidney failure, Significant chronic heart failure, Significant chronic respiratory failure, Previous anaphylactic reaction to the IMP or AMP

研究者

发起方
niversity Hospital Of North Norway HF

相似试验